Inhibikase Therapeutics, Inc. Operating Cash Flow
Inhibikase Therapeutics, Inc. (IKT) reported Operating Cash Flow of -$24.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$12.44M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.06M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$7.52M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$10.59M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$27.79M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$19.15M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$18.09M.
- Inhibikase Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$17.35M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$24.50M 10-Q · filed 2026-08-11 | -$32.02M derived: sum of 3 quarters · filed 2026-08-11 | -$42.61M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$12.06M 10-Q · filed 2026-05-12 | -$19.58M derived: sum of 2 quarters · filed 2026-05-12 | -$30.17M derived: sum of 3 quarters · filed 2026-05-12 | -$35.74M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$7.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$18.11M derived: sum of 2 quarters · filed 2026-03-26 | -$23.68M derived: sum of 3 quarters · filed 2026-08-11 | -$27.79M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$10.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$16.17M derived: sum of 2 quarters · filed 2026-08-11 | -$20.27M 10-Q · filed 2025-11-14 | -$25.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$5.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$9.68M 10-Q · filed 2026-08-11 | -$15.02M derived: sum of 3 quarters · filed 2026-08-11 | -$19.90M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$4.10M 10-Q · filed 2026-05-12 | -$9.45M derived: sum of 2 quarters · filed 2026-05-12 | -$14.33M derived: sum of 3 quarters · filed 2026-05-12 | -$19.38M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$5.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$10.23M derived: sum of 2 quarters · filed 2026-03-26 | -$15.28M derived: sum of 3 quarters · filed 2026-03-26 | -$19.15M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$4.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$9.94M derived: sum of 2 quarters · filed 2025-11-14 | -$13.80M 10-Q · filed 2025-11-14 | -$17.24M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$8.92M 10-Q · filed 2025-08-14 | -$12.36M derived: sum of 3 quarters · filed 2025-08-14 | -$16.47M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.87M 10-Q · filed 2025-05-14 | -$7.31M derived: sum of 2 quarters · filed 2025-05-14 | -$11.41M derived: sum of 3 quarters · filed 2025-05-14 | -$15.98M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$7.55M derived: sum of 2 quarters · filed 2025-03-27 | -$12.11M derived: sum of 3 quarters · filed 2025-03-27 | -$18.09M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$4.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$8.67M derived: sum of 2 quarters · filed 2024-11-14 | -$14.64M 10-Q · filed 2024-11-14 | -$18.20M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$10.54M 10-Q · filed 2024-08-14 | -$14.09M derived: sum of 3 quarters · filed 2024-08-14 | -$19.60M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$5.97M 10-Q · filed 2024-05-15 | -$9.53M derived: sum of 2 quarters · filed 2024-05-15 | -$15.03M derived: sum of 3 quarters · filed 2024-05-15 | -$19.39M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$9.06M derived: sum of 2 quarters · filed 2024-03-27 | -$13.42M derived: sum of 3 quarters · filed 2024-03-27 | -$17.35M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$9.86M derived: sum of 2 quarters · filed 2023-11-14 | -$13.79M 10-Q · filed 2023-11-14 | -$17.89M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$4.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$8.29M 10-Q · filed 2023-08-14 | -$12.39M derived: sum of 3 quarters · filed 2023-08-14 | -$14.41M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.93M 10-Q · filed 2023-05-15 | -$8.03M derived: sum of 2 quarters · filed 2023-05-15 | -$10.05M derived: sum of 3 quarters · filed 2023-05-15 | -$14.30M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$6.12M derived: sum of 2 quarters · filed 2023-03-31 | -$10.36M derived: sum of 3 quarters · filed 2023-03-31 | -$14.30M 10-K · filed 2023-03-31 |
| 2021-09-30 | -$2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$6.27M derived: sum of 2 quarters · filed 2022-11-14 | -$10.20M 10-Q · filed 2022-11-14 | -$11.15M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$8.18M 10-Q · filed 2022-08-12 | -$9.13M derived: sum of 3 quarters · filed 2022-08-12 | -$9.05M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$3.93M 10-Q · filed 2022-05-16 | -$4.88M derived: sum of 2 quarters · filed 2022-05-16 | -$4.81M derived: sum of 3 quarters · filed 2022-05-16 | -$4.81M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$946.53K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$871.01K derived: sum of 2 quarters · filed 2022-03-31 | -$873.92K derived: sum of 3 quarters · filed 2022-03-31 | -$1.13M 10-K · filed 2022-03-31 |
| 2020-09-30 | $75.52K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $72.61K derived: sum of 2 quarters · filed 2021-11-15 | -$182.83K 10-Q · filed 2021-11-15 | |
| 2020-06-30 | -$2.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$258.34K 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | -$255.43K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |